Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
© 2025 Recce Pharmaceuticals